13. Intangible assets other than goodwill
(thousands of €) |
Software & |
Licences, rights, technology and |
Contract costs |
Total |
|---|---|---|---|---|
Acquisition value |
|
|
|
|
|
|
|
|
|
On 1 January 2021 |
23,717 |
44,432 |
15,384 |
83,534 |
Additions |
2,423 |
1,250 |
|
3,673 |
Sales and disposals |
(1,643) |
(5,753) |
|
(7,396) |
Translation differences |
57 |
|
|
57 |
On 31 December 2021 |
24,554 |
39,929 |
15,384 |
79,868 |
Impact of acquisitions of businesses |
|
124,570 |
|
124,562 |
Additions |
1,126 |
8,423 |
|
9,557 |
Sales and disposals |
(913) |
(36,298) |
|
(37,211) |
Translation differences |
|
(36) |
|
(36) |
On 31 December 2022 |
24,767 |
136,588 |
15,384 |
176,740 |
|
|
|
|
|
Amortization and impairment |
|
|
|
|
|
|
|
|
|
On 1 January 2021 |
10,034 |
3,883 |
2,050 |
15,968 |
Amortization |
3,529 |
2,053 |
1,538 |
7,120 |
Impairment |
|
4,016 |
|
4,016 |
Sales and disposals |
(1,643) |
(5,753) |
|
(7,396) |
Translation differences |
57 |
|
|
57 |
On 31 December 2021 |
11,977 |
4,199 |
3,588 |
19,765 |
Amortization |
3,967 |
6,666 |
1,538 |
12,171 |
Impairment |
|
35,666 |
|
35,666 |
Sales and disposals |
(913) |
(36,298) |
|
(37,211) |
Translation differences |
|
(4) |
|
(4) |
On 31 December 2022 |
15,031 |
10,229 |
5,126 |
30,387 |
|
|
|
|
|
Carrying amount |
|
|
|
|
|
|
|
|
|
On 31 December 2021 |
12,577 |
35,730 |
11,796 |
60,103 |
On 31 December 2022 |
9,736 |
126,359 |
10,258 |
146,354 |
Impact of acquisition of businesses in 2022 refers to the acquisition of CellPoint and AboundBio. We refer to note 26 “Business combinations during the period”.
New additions in 2022 primarily related to the capitalization of an in-licensing fee for an amount of €7.5 million and of a milestone payment of $1.0 million, and software acquisitions for a total amount of €1.1 million.
In 2022 we recorded an impairment of €26.7 million on previously capitalized upfront fees related to our collaboration with Molecure on the dual chitinase inhibitor OATD-01 (GLPG4716) in fibrosis, and impairments of €8.9 million on intangible assets related to other discontinued projects.
On 31 December 2022, our balance sheet did not hold any internally generated assets capitalized as intangible asset.